JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 16 February 2006. doi:10.1136/jcp.2005.028209
Journal of Clinical Pathology 2006;59:403-409
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2005.028209v1
59/4/403    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burkhardt, M
Right arrow Articles by Kristiansen, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burkhardt, M
Right arrow Articles by Kristiansen, G
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Breast Cancer

ORIGINAL ARTICLE

Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer

M Burkhardt1,*, E Mayordomo1,*, K-J Winzer2, F Fritzsche1, T Gansukh1, S Pahl1, W Weichert1, C Denkert1, H Guski1, M Dietel1, G Kristiansen1

1 Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany
2 Interdisciplinary Breast Centre, Charité-Universitätsmedizin

Correspondence to:
Dr Glen Kristiansen
Institute of Pathology, Charité Hospital, Campus Mitte, Schumannstr 20/21, D-10117 Berlin, Germany; glen.kristiansen{at}charite.de Background: Activated leucocyte cell adhesion molecule (ALCAM, CD166) is a cell surface member of the immunoglobulin superfamily. ALCAM expression has prognostic relevance in prostate and colon cancer.

Objective: To evaluate ALCAM protein expression in breast cancer by immunohistochemistry and to correlate expression levels with clinicopathological data.

Methods: 162 primary breast carcinomas with a mean clinical follow up time of 53 months were immunostained using a monoclonal ALCAM antibody. The staining was evaluated as an immunoreactive score (IRS) and grouped into low v high for both membranous and cytoplasmic staining.

Results: Intraductal and invasive carcinomas showed a higher ALCAM expression (median IRS 4 and 6 respectively) than normal breast tissue (IRS 2). In univariate survival analyses a significant association of high cytoplasmic ALCAM expression with shortened patient disease-free survival (mean (SD) five year non-progression rate, 69.4 (4.6)% v 49.4 (11.1)%, p = 0.0142) was found. In multivariate analyses of disease-free survival times, high cytoplasmic ALCAM expression (relative risk (RR) = 2.086, p = 0.026) and nodal status (RR = 2.246, p = 0.035) were significantly associated with earlier disease progression, whereas tumour grading (RR = 1.6, p = 0.052) was of borderline significance.

Conclusions: The data suggest that strong cytoplasmic ALCAM expression in primary breast cancer, as detected by immunohistochemistry, might be a new marker for a more aggressive breast cancer biology.


Abbreviations: ALCAM, activated leucocyte cell adhesion molecule; DCIS, ductal carcinoma in situ; IRS, immunoreactive score

Keywords: breast cancer; ALCAM; prognostic marker; immunohistochemistry




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. Mezzanzanica, M. Fabbi, M. Bagnoli, S. Staurengo, M. Losa, E. Balladore, P. Alberti, L. Lusa, A. Ditto, S. Ferrini, et al.
Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients
Clin. Cancer Res., March 15, 2008; 14(6): 1726 - 1733.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
O. Rosso, T. Piazza, I. Bongarzone, A. Rossello, D. Mezzanzanica, S. Canevari, A. M. Orengo, A. Puppo, S. Ferrini, and M. Fabbi
The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells
Mol. Cancer Res., December 1, 2007; 5(12): 1246 - 1253.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Kobayashi, H. Kubo, T. Suzuki, K. Ishizawa, M. Yamada, M. He, Y. Yamamoto, H. Yamamoto, H. Sasano, H. Sasaki, et al.
Endogenous Secretory Receptor for Advanced Glycation End Products in Non-Small Cell Lung Carcinoma
Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 184 - 189.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.